Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
National Institutes of Health has announced on 09 May 2022
that is accepting bids for the following project: Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional).
The tender will take place in United States
and will cover the Education & Training industry.
The value of this project has not been disclosed by the donor and you can apply until Deadline date
After the deadline, Global Database will announce the contract award for Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional).
In order to stay
up-to-date with this tender and also to receive daily notifications about similar projects, you can subscribe to our
newsletter for free.
Bellow you can find more information about the tender description and the bidding procedure.
Description
https://www.grants.gov/grantsws/rest/opportunity/details 340174
The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain. Research of interest includes but is not limited to Stage I research.